Multiple Myeloma With Failed Remission
5 clinical trials · Condition
◉ Watch Multiple Myeloma With Failed Remission
| Record | Firm | Date |
|---|---|---|
| Study of HPN217 in Participants With Relapsed/Refractory Multiple Myeloma MK-4002 (MK-4002-001) (NCT04184050) | Harpoon Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 2020-04-13 |
| A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) (NCT03650491) | Fortis Therapeutics, Inc. | 2019-04-03 |
| Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma (NCT03428373) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2019-01-17 |
| Tinostamustine Conditioning and Autologous Stem Cell (NCT03687125) | Mundipharma-EDO GmbH | 2018-10-15 |
Track Multiple Myeloma With Failed Remission automatically
Every clearance here is in the API, with alerts when new ones post.